No Survival Benefit from Lymph Node Dissection in Biopsy-Positive Melanoma
In sentinel node biopsy (SLNB)-positive melanoma, no survival benefit was achieved by complete lymph node dissection (CLND).
In sentinel node biopsy (SLNB)-positive melanoma, no survival benefit was achieved by complete lymph node dissection (CLND).
Bortezomib consolidation significantly improved progression-free survival compared with observation in multiple myeloma.
Daratumumab demonstrated profound durable activity with meaningful responses in patients with heavily pretreated multiple myeloma.
Long-term data do not support efficacy of primary temozolomide monotherapy versus radiotherapy in anapestic glioma.
Tumor Treating Fields improved progression-free survival and overall survival in patients with newly diagnosed glioblastoma.
Patients managed without radiotherapy after neoadjuvant chemotherapy for breast cancer have a significantly worse outcome.
Etirinotecan pegol provided a clinically meaningful benefit to patients with late-stage advanced breast cancer.
Pembrolizumab immunotherapy is effective in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Panitumumab plus accelerated fractionation radiotherapy (AFX) was not superior in squamous cell carcinoma of the head and neck.
Complete response rate at 30 months is a surrogate endpoint for progression-free survival in first-line follicular lymphoma trials.